Back to top
more

Novo Nordisk (NVO)

(Real Time Quote from BATS)

$132.44 USD

132.44
582,250

+0.90 (0.68%)

Updated Jul 22, 2024 10:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 28% (181 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Impax Laboratories and Amneal Pharmaceuticals Agree to Merge

Impax Laboratories (IPXL) and Amneal Pharmaceuticals announced an agreement to merge to form a new publicly traded company.

    Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals

    Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals

      Sanofi/Regeneron's Dupixent Succeeds in Phase II Study

      Sanofi (SNY) and Regeneron's phase II study evaluating Dupixent for the treatment of adults with active moderate-to-severe eosinophilic esophagitis meets its primary endpoint.

        Immune Design's Sarcoma Candidate to Enter Phase III in 2018

        Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.

          Bristol-Myers Gets Priority Review for Opdivo Label Expansion

          Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.

            Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada

            GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.

              Why Should You Invest in Novo Nordisk (NVO) Stock Right Now

              Novo Nordisk (NVO) has a strong presence in the Diabetes care market and the current quarter has seen some events happening for the company that bode well for its growth.

                4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3

                The Large Cap Pharmaceuticals industry has gained 20.7% year to date, outpacing 14.7% gain for the S&P 500.

                  Johnson & Johnson Files sNDA for Label Expansion of Invokana

                  Johnson & Johnson (JNJ) filed a supplemental New Drug Application to the FDA for the label expansion of Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular events in adults with type II diabetes.

                    Novo Nordisk's Fiasp Gets FDA Nod for Diabetes in Adults

                    Novo Nordisk's (NVO) fast-acting mealtime insulin aspart, Fiasp, has been approved by the FDA for the treatment of adults with diabetes.

                      Orexigen's (OREX) Contrave Sales Improving on Promotions

                      Despite competition, Orexigen Therapeutics' (OREX) obesity drug, Contrave has performed well so far this year driven by the company's promotional strategies.

                        Arpita Dutt headshot

                        3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day

                        With World Heart Day coming up, here is a look at some well-positioned stocks including BioTelemetry (BEAT) in this segment of the market.

                          Pfizer's Sutent Label Expansion Gets Mixed FDA Committee View

                          Pfizer's (PFE) cancer drug Sutent gets a mixed opinion from an FDA advisory committee regarding a regulatory application, which was filed to expand its label.

                            The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk

                            The Zacks Analyst Blog Highlights: Apple, Pfizer, Carnival, T. Rowe Price and Novo Nordisk

                              Mark Vickery headshot

                              Top Analyst Reports for Apple, Pfizer & Carnival

                              Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Pfizer (PFE) and Carnival (CCL).

                                Teva Hires Kare Schultz as CEO: Is a Recovery in the Cards?

                                Teva Pharmaceutical (TEVA) announced the appointment of H. Lundbeck's Kare Schultz as President and Chief Executive Officer (CEO).

                                  Novo Nordisk's Tresiba Gets Canadian Nod

                                  Novo Nordisk's (NVO) Tresiba is approved by Health Canada for the once-daily treatment of adults with diabetes mellitus to improve glycemic control.

                                    Novo Nordisk's Victoza Gets FDA Nod for Label Expansion

                                    Novo Nordisk's (NVO) Victoza receives FDA nod for its label expansion to include cardiovascular events in adult patients with type II diabetes. Shares up.

                                      The Zacks Analyst Blog Highlights: Pfizer, TJX Companies, Honda, American Electric and Novo Nordisk

                                      The Zacks Analyst Blog Highlights: Pfizer, TJX Companies, Honda, American Electric and Novo Nordisk

                                        Novo Nordisk's Semaglutide Shows Remarkable Results in Study

                                        Novo Nordisk (NVO) pipeline candidate shows superior glucose control and weight loss in study in diabetes patients compared with Eli Lilly and Co's Trulicity (dulaglutide).

                                          Novo Nordisk (NVO) Beats on Q2 Earnings, Revenues Miss

                                          Novo Nordisk A/S (NVO) beat earnings estimates but missed revenue estimates in Q2. Robust performance for Victoza and Tresiba will drive growth.

                                            Why Earnings Season Could Be Great for Novo Nordisk (NVO)

                                            Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                              Allergan (AGN) to Report Q2 Earnings: What's in the Cards?

                                              While Allergan plc's (AGN) Q2 sales are likely to be driven by new as well as established products and international growth, earnings will likely be driven by sales growth and cost control.

                                                Is a Beat in the Cards for Pfizer (PFE) in Q2 Earnings?

                                                While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.

                                                  AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?

                                                  AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.